Scott Gottlieb
Scott Gottlieb's purchase track record
How the stock did after each of Scott Gottlieb's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/9/2026 | ILMN | $24K | +21.5% | +63.6% | +11.3% |
| 11/3/2025 | ILMN | $61K | +17.6% | +16.2% | +5.1% |
| 10/30/2024 | PFE | $28K | -3.6% | -11.6% | -4.2% |
| 12/15/2023 | PFE | $79K | +6.5% | +6.5% | +15.1% |
| 5/5/2023 | PFE | $77K | -7.0% | -17.0% | +5.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tempus AI Expands Collaborations, Canaccord Raises Target to $95. Tempus AI is expanding its strategic collaborations to support future growth. Canaccord Genuity recently raised its price target for the stock to $95. This development occurs as the company prepares to report its third-quarter financial results on November 2.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff. Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.
Transaction History
| UNH | ▲ Buy | Grant | 5 | $0 | 9/22/2026 | View on chart |
| UNH | ▲ Buy | Grant | 210 | $0 | 7/1/2026 | View on chart |
| UNH | ▲ Buy | Grant | 3 | $0 | 6/23/2026 | View on chart |
| ILMN | ▲ Buy | Grant | 2,072 | $300K | 5/21/2026 | View on chart |
| TEM | ▲ Buy | Grant | 5,913 | $0 | 5/21/2026 | View on chart |
| UNH | ▲ Buy | Grant | 320 | $0 | 4/1/2026 | View on chart |
| UNH | ▲ Buy | Grant | 1 | $0 | 3/17/2026 | View on chart |
| ILMN | ▲ Buy | Open Market | 200 | $24K | 2/9/2026 | View on chart |
| UNH | ▲ Buy | Grant | 125 | $0 | 1/2/2026 | View on chart |
| ILMN | ▲ Buy | Open Market | 500 | $61K | 11/3/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 3,780 | $0 | 5/21/2025 | View on chart |
| TEM | ▲ Buy | Grant | 1,997 | $0 | 5/20/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 16,273 | $766K | 4/1/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 4,000 | $193K | 4/1/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 2,558 | $125K | 4/1/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 5,006 | $231K | 4/1/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 3,077 | $146K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 7,102 | $358K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 4,612 | $215K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 6,349 | $308K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 6,698 | $333K | 3/17/2025 | View on chart |
| PFE | ▲ Buy | Open Market | 1,000 | $28K | 10/30/2024 | View on chart |
| TEM | ▲ Buy | Grant | 88,514 | $0 | 6/13/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 2,622 | $0 | 5/16/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 220 | $25K | 12/29/2023 | View on chart |
| PFE | ▲ Buy | Open Market | 3,000 | $79K | 12/15/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 142 | $24K | 9/29/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 103 | $21K | 6/30/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 1,532 | $0 | 5/26/2023 | View on chart |
| PFE | ▲ Buy | Open Market | 1,000 | $39K | 5/8/2023 | View on chart |
| PFE | ▲ Buy | Open Market | 1,000 | $38K | 5/5/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 100 | $21K | 3/31/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 1,232 | $0 | 5/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
UnitedHealth Q3 Margins Rise, Membership Declines, Stock Volatility
UnitedHealth Group reported that Q3 operating margins improved while membership numbers slipped, a mix that could reshape the company's growth outlook. The earnings beat sparked a sharp 51% drop followed by a 40% rebound, reflecting market uncertainty. Analysts note that guidance revisions this earnings season may influence future performance.
UnitedHealth Q3 Margins Rise, Membership Declines, Stock Volatility. UnitedHealth Group reported that Q3 operating margins improved while membership numbers slipped, a mix that could reshape the company's growth outlook. The earnings beat sparked a sharp 51% drop followed by a 40% rebound, reflecting market uncertainty. Analysts note that guidance revisions this earnings season may influence future performance.